Oliceridine injection, our lead product candidate, is a G protein-selective agonist at the mu‑opioid receptor being developed for the management of moderate to severe acute pain in hospitals or other controlled clinical settings where intravenous, or IV, opioid therapy is warranted.
Our pipeline includes several additional product candidates we have identified as potential best- or first-in-class therapies for a variety of critical unmet medical needs. These are all new molecules discovered by Trevena scientists using our proprietary platform.
September 27, 2019Trevena to Present at the 2019 Cantor Global Healthcare Conference
September 3, 2019Trevena to Participate in Upcoming Conferences in September 2019
August 28, 2019Trevena Advances NDA Resubmission Activities for Oliceridine
Copyright © Trevena, Inc.